ECSP034505A - La sal de clorhidrato de 5-[4-(2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2, 4-diona - Google Patents

La sal de clorhidrato de 5-[4-(2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2, 4-diona

Info

Publication number
ECSP034505A
ECSP034505A EC2003004505A ECSP034505A ECSP034505A EC SP034505 A ECSP034505 A EC SP034505A EC 2003004505 A EC2003004505 A EC 2003004505A EC SP034505 A ECSP034505 A EC SP034505A EC SP034505 A ECSP034505 A EC SP034505A
Authority
EC
Ecuador
Prior art keywords
amino
methyl
tiazolidin
piridil
etoxi
Prior art date
Application number
EC2003004505A
Other languages
English (en)
Inventor
Andrew Simon Craig
Michael Millan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ECSP034505A publication Critical patent/ECSP034505A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un compuesto farmacéutico novedoso, clorhidrato de 5-(4-(2-(N-metil-N-(2-piridil)amino)etoxi)bencil)tiazolidin-4, 4-diona, un procedimiento para preparar dicho compuesto, farmacéutica que comprende dicho compuesto y el uso de dicho y el uso de dicho compuesto en la medicina.
EC2003004505A 2000-09-06 2003-03-06 La sal de clorhidrato de 5-[4-(2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2, 4-diona ECSP034505A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0021865.1A GB0021865D0 (en) 2000-09-06 2000-09-06 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
ECSP034505A true ECSP034505A (es) 2003-06-25

Family

ID=9898953

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004505A ECSP034505A (es) 2000-09-06 2003-03-06 La sal de clorhidrato de 5-[4-(2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2, 4-diona

Country Status (35)

Country Link
US (3) US20040034066A1 (es)
EP (1) EP1315723B1 (es)
JP (1) JP2004508369A (es)
KR (1) KR100770513B1 (es)
CN (1) CN100558717C (es)
AP (1) AP1715A (es)
AT (1) ATE300538T1 (es)
AU (2) AU8428401A (es)
BG (1) BG107607A (es)
BR (1) BR0113713A (es)
CA (1) CA2421213A1 (es)
CY (1) CY1105252T1 (es)
CZ (1) CZ302125B6 (es)
DE (1) DE60112310T2 (es)
DK (1) DK1315723T3 (es)
DZ (1) DZ3475A1 (es)
EA (1) EA004296B1 (es)
EC (1) ECSP034505A (es)
ES (1) ES2244647T3 (es)
GB (1) GB0021865D0 (es)
HK (1) HK1057749A1 (es)
HU (1) HUP0300938A3 (es)
IL (2) IL154724A0 (es)
MA (1) MA25908A1 (es)
MX (1) MXPA03001956A (es)
NO (1) NO324020B1 (es)
NZ (1) NZ524548A (es)
OA (1) OA12375A (es)
PL (1) PL360578A1 (es)
PT (1) PT1315723E (es)
SI (1) SI1315723T1 (es)
SK (1) SK2632003A3 (es)
UA (1) UA74003C2 (es)
WO (1) WO2002020519A1 (es)
ZA (1) ZA200301809B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP5063714B2 (ja) * 2010-01-29 2012-10-31 シャープ株式会社 画像読取装置及び画像形成装置
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
RU2487132C1 (ru) * 2012-07-23 2013-07-10 Общество с ограниченной ответственностью "Метаген" Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DK0896182T3 (da) * 1997-07-17 2002-07-29 Interlemo Holding Sa Sammenkoblingssystem
CN1183130C (zh) * 1999-09-24 2005-01-05 中国人民解放军军事医学科学院毒物药物研究所 噻唑烷类衍生物及其医药用途
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
BR0113713A (pt) 2004-07-06
AU8428401A (en) 2002-03-22
WO2002020519A1 (en) 2002-03-14
IL154724A (en) 2009-07-20
UA74003C2 (en) 2005-10-17
ES2244647T3 (es) 2005-12-16
MA25908A1 (fr) 2003-10-01
CZ302125B6 (cs) 2010-11-03
KR100770513B1 (ko) 2007-10-25
JP2004508369A (ja) 2004-03-18
AP1715A (en) 2007-02-28
DZ3475A1 (fr) 2002-03-14
DK1315723T3 (da) 2005-10-24
CZ2003615A3 (cs) 2003-11-12
AU2001284284B2 (en) 2005-08-04
OA12375A (en) 2004-03-19
AP2003002758A0 (en) 2003-06-30
EP1315723B1 (en) 2005-07-27
IL154724A0 (en) 2003-10-31
NO20031020D0 (no) 2003-03-05
HUP0300938A3 (en) 2005-04-28
ZA200301809B (en) 2004-04-19
ATE300538T1 (de) 2005-08-15
MXPA03001956A (es) 2003-06-24
US20070191435A1 (en) 2007-08-16
KR20030027118A (ko) 2003-04-03
NO324020B1 (no) 2007-07-30
EA004296B1 (ru) 2004-02-26
NZ524548A (en) 2004-10-29
PT1315723E (pt) 2005-11-30
CA2421213A1 (en) 2002-03-14
BG107607A (bg) 2003-12-31
US20050282867A1 (en) 2005-12-22
EA200300345A1 (ru) 2003-08-28
PL360578A1 (en) 2004-09-06
CN100558717C (zh) 2009-11-11
DE60112310T2 (de) 2006-02-09
CY1105252T1 (el) 2010-03-03
GB0021865D0 (en) 2000-10-18
US20040034066A1 (en) 2004-02-19
NO20031020L (no) 2003-05-06
EP1315723A1 (en) 2003-06-04
DE60112310D1 (de) 2005-09-01
HUP0300938A2 (hu) 2003-11-28
SK2632003A3 (en) 2003-12-02
CN1366520A (zh) 2002-08-28
SI1315723T1 (en) 2005-10-31
HK1057749A1 (en) 2004-04-16

Similar Documents

Publication Publication Date Title
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
CY1106226T1 (el) Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης
CY1105252T1 (el) Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης
CY1105354T1 (el) Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο
CY1107252T1 (el) Τρυγικο αλας παραγωγου της θειζολιδινοδιονης
ECSP034469A (es) Compuesto farmaceutico novedoso
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
EA200300231A1 (ru) Тартратные соли производного тиазолидиндиона
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
ECSP034528A (es) Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona
CY1106397T1 (el) Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο
ECSP034529A (es) Derivado de tiazolidinodiona y su uso como antidiabetico
EA200300232A1 (ru) Тартратные соли производного тиазолидиндиона
ECSP003434A (es) Nuevos compuestos
ECSP003435A (es) Nuevos compuestos